Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Immune Responses to Vaccines in Patients with Hematologic Diseases
share announcement

Immune Responses to Vaccines in Patients with Hematologic Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: closed (31 January 2025) | Viewed by 2046

Special Issue Editor

Prof. Dr. Monia Marchetti

E-Mail Website
Guest Editor
Haematology and Transplant Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo,15121 Alessandria, Italy
Interests: chronic myeloproliferative neoplasms; acute myeloid leukemia; anti-cancer vaccines; immune responses to COVID-19 vaccines in patients with hematologic diseases; evidence-based medicine; clinical practice guidelines; pharmacoeconomic analysis; decision analysis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Patients with rare blood cancers (blood neoplasms) faced challenges during the COVID-19 pandemic until active and passive measures were implemented. The severity of the disease is influenced by various factors, such as the patient’s immunity and treatment. The safety and efficacy of disease measures may vary depending on the SARS-CoV-2 variant and the disease epidemiology. To address these issues, this Special Issue will gather an important collection of articles that explore the latest research and development efforts in this field. We welcome original articles, reviews, and viewpoints covering vaccines and the experiences of hematologists and infectious disease specialists who have treated blood neoplasm patients with SARS-CoV-2.

Prof. Dr. Monia Marchetti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SARS-CoV-2
  • COVID-19
  • leukemia
  • lymphoma
  • multiple myeloma
  • chronic myeloproliferative neoplasms
  • immune thrombocytopenia
  • tixagevimab/cilgavimab

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 2435 KiB  
Article
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma
by Khalid Shoumariyeh, Benedikt Csernalabics, Elahe Salimi Alizei, Matthias Reinscheid, Sebastian Giese, Kevin Ciminski, Georg Kochs, Martin Schwemmle, Julia Lang-Meli, Michelle Maas, Natascha Roehlen, Vivien Karl, Anne Graeser, Oezlem Sogukpinar, Ivana von Metzler, Denise Grathwohl, Leo Rasche, Holger Hebart, Miriam Kull, Florian Emmerich, Cornelius Florian Waller, Justus Duyster, Monika Engelhardt, Tanja Nicole Hartmann, Bertram Bengsch, Tobias Boettler, Christoph Neumann-Haefelin, Maike Hofmann, Robert Thimme and Hendrik Luxenburgeradd Show full author list remove Hide full author list
Vaccines 2024, 12(11), 1249; https://doi.org/10.3390/vaccines12111249 - 1 Nov 2024
Viewed by 1670
Abstract
Background: Multiple myeloma (MM) patients are at high risk of severe infections including COVID-19 due to an immune dysregulation affecting both innate and adaptive immune responses. However, our understanding of the immune responses to infection and vaccination in MM patients is limited. To [...] Read more.
Background: Multiple myeloma (MM) patients are at high risk of severe infections including COVID-19 due to an immune dysregulation affecting both innate and adaptive immune responses. However, our understanding of the immune responses to infection and vaccination in MM patients is limited. To gain more detailed insights into infection- and vaccine-elicited T cell immunity in MM, we studied the CD8+ T cell response on the single-epitope level in SARS-CoV-2 convalescent and mRNA-vaccinated MM patients. Methods: We compared peptide/MHC class I tetramer-enriched SARS-CoV-2-specific CD8+ T cells and antibody responses in MM patients (convalescent: n = 16, fully vaccinated: n = 5, vaccinated convalescent: n = 5) and healthy controls (HCs) (convalescent: n = 58, fully vaccinated: n = 7) either after infection with SARS-CoV-2 alone, complete mRNA vaccination or SARS-CoV-2 infection and single-shot mRNA vaccination (hybrid immunity). Results: MM patients have lower frequencies and a lower proportion of fully functional virus-specific CD8+ T cells compared to HCs, after both SARS-CoV-2 infection and vaccination. CD8+ T cell memory subset distribution in MM patients is skewed towards reduced frequencies of central memory (TCM) T cells and higher frequencies of effector memory 1 (TEM1) T cells. In contrast, the humoral immune response was comparable in both cohorts after viral clearance. Notably, CD8+ T cell frequencies as well as the humoral immune response were improved by a single dose of mRNA vaccine in convalescent MM patients. Conclusions: MM patients have relative immunological deficiencies in SARS-CoV-2 immunity but benefit from hybrid immunity. These findings underline the relevance of vaccinations in this vulnerable patient group. Full article
(This article belongs to the Special Issue Immune Responses to Vaccines in Patients with Hematologic Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop